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Abstract 
Background: Based on findings that major depressive disorder (MDD) is associated to decreased 
dorsolateral prefrontal cortical (DLPFC) activity; interventions that increase DLPFC activity might 
theoretically present antidepressant effects. Two of them are cognitive control therapy (CCT), a 
neurobehavioral intervention that uses computer-based working memory exercises, and transcranial 
direct current stimulation (tDCS), which delivers weak, electric direct currents over the scalp.  
Methods: We investigated whether tDCS enhanced the effects of CCT in a double-blind trial, in 
which participants were randomized to sham tDCS and CCT (n=17) vs. active tDCS and CCT 
(n=20). CCT and tDCS were applied for 10 consecutive workdays. Clinicaltrials.gov 
identifier:NCT01434836. 
Results: Both CCT alone and combined with tDCS ameliorated depressive symptoms after the 
acute treatment period and at follow-up, with a response rate of approximately 25%. Older patients 
and those who presented better performance in the task throughout the trial (possibly indicating 
greater engagement and activation of the DLPFC) had greater depression improvement in the 
combined treatment group.  
Limitations: Our exploratory findings should be further confirmed in prospective controlled trials. 
Discussion: CCT and tDCS combined might be beneficial for older depressed patients, particularly 
for thosewho have cognitive resources to adequately learn and improve task performance over time. 
This combined therapy might be specifically relevant in this subgroup that is more prone to present 
cognitive decline and prefrontal cortical atrophy. 
Keywords 
Major depressive disorder; transcranial direct current stimulation; control cognitive therapy; non-
invasive brain stimulation; randomized clinical trial; geriatric depression.  
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1. Introduction 
 Considerable research has been performed on novel treatments for major depression, a 
chronic, highly prevalent disorder (Kessler et al., 2003) in which antidepressant drugs present 
modest efficacy (Trivedi et al., 2006) and important adverse effects (Anderson et al., 2008) that 
limit their use. Some of these novel interventions aim to improve depression symptoms by directly 
increasing dorsolateral prefrontal cortical (DLPFC) activity, based on the observation of decreased 
activity of this area and increased activity of subcortical structures observed in MDD, a pattern that 
is at least partially restored to normal levels after amelioration of depressive symptoms (Mayberg et 
al., 2000; Pizzagalli, 2011; Siegle et al., 2007). Two of these interventions are particularly 
appealing considering their low cost, ease of use and applicability in different scenarios: 
transcranial direct current stimulation (tDCS) and neurobehavioral therapies.  
TDCS consists of the induction of a weak, direct electric current through electrodes placed 
over the scalp that could increase (anode) and decrease (cathode) cortical excitability beyond the 
period of stimulation(Nitsche and Paulus, 2000). Although the exact mechanisms of action of tDCS 
are still unclear, it probably operates by inducing small changes (<1mV) in the membrane 
potential(Datta et al., 2009), thus acting in the frequency of spike timing and modifying net cortical 
excitability(Purpura and McMurtry, 1965). Compared to repetitive transcranial magnetic 
stimulation (rTMS), another somatic therapy, tDCS is cheaper, easier to use and a more portable 
technique with less adverse effects (Priori et al., 2009); characteristics that have motivated further 
tDCS research in neuropsychiatric disorders, particularly depression. In fact, recent randomized 
clinical trials demonstrated that daily, repeated sessions of tDCS show clinical efficacy in the 
treatment of major depression (Brunoni et al., 2013c; Loo et al., 2012). These studies applied 
anodal tDCS over the left DLPFC, theoretically increasing the activity in this brain area, which is 
decreased in MDD. 
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Neurobehavioral therapy is an intervention that addresses the biological mechanisms of 
psychological disorders (Siegle et al., 2007). For depression, current neurobehavioral interventions 
consist of tasks focused on working memory and sustained attention training, as these cognitive 
tasks are associated with DLPFC activity – in fact, patients with depression have poorer 
performance in many of these tasks (Barch et al., 2003; Gotlib and Joormann, 2010; Jones et al., 
2010). In recent studies, Siegle et al. (2007; In press) investigated whether these interventions that 
increase DLPFC activity could be employed as a depression treatment. The authors compared the 
outcome of depressed patients that were randomized to receive treatment as usual only vs. 
combined with cognitive control therapy (CCT) designed to increase DLPFC activity. They showed 
that the CCT group displayed significantly greater improvements in depression symptoms than 
those in the treatment as usual group. In another study, Segrave et al. (2013) explored the efficacy 
of CCT combined with tDCS in a 3-arm trial, randomizing 27 patients to receive CCT + sham tDCS, 
tDCS + sham CCT and both active therapies combined, finding that only CCT and tDCS combined 
presented sustained antidepressant response at follow-up. However, the sample size of this study 
was small (N=9 per condition) andthe number of sessions was limited (5 sessions). These promising 
results fostered further investigation in this topic.  
Both tDCS and CCT might act in depression improvement via enhancement of DLPFC 
activity. Theoretically, tDCS could enhance - i.e., present synergistic effects – the influence of CCT, 
based on previous studies that showed that tDCS increases WM performance in healthy and 
depressed volunteers (Brunoni and Vanderhasselt, in press; Fregni et al., 2005; Oliveira et al., 2013). 
We examined whether tDCS, by increasing cortical activity in the DLPFC, could enhance 
performance and therefore the effects of CCT, which actively recruits similar brain areas, thus 
ameliorating depression. Importantly, we used the Paced Auditory Serial Addition Task (PASAT) 
training alone (and not combined to the computer-based attention training part as used in the 
Segrave et al. study) for CCT, because by using two tasks it is impossible to disentangle the specific 
contribution of each task. We used the PASAT because this task is already known to activate the 
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left middle frontal gyrus, including the DLPFC (Lazeron et al., 2003). The importance of this study 
is both mechanistic – i.e., to increase the understanding of the pathophysiological mechanisms 
involved in depression – and clinical, as we investigated whether the combination of two non-
pharmacological, affordable therapies presented clinical gains in depressed subjects.  
 
2. Methods 
The study was approved by the Local and National Ethics Committee and is registered in 
clinicaltrials.gov (NCT01434836). All patients provided written, informed consent. The trial was 
conducted in the University Hospital, University of São Paulo, Brazil and in the Mackenzie 
Presbyterian University, also situated in São Paulo, Brazil from September 2011 to May 2013. 
 
Subjects 
 We enrolled patients from both genders with acute depressive disorder according to the 
evaluation of board-certified psychiatrists (ARB and LCLV) who confirmed the diagnosis using the 
Portuguese-validated version of the Mini International Neuropsychiatric Inventory (Amorim, 2000 ). 
Only those with a 24-item Hamilton Depression Rating Score (HDRS) greater than 21, with low 
suicide risk and aged between 18 and 65 years were included. We did not include patients who 
presented any of the following: (1) other psychiatric disorders, notably bipolar disorder, substance 
use disorders and schizophrenia, except for anxiety disorders whencomorbid with depression; (2) 
personality disorders; (3) previous neurologic conditions (i.e., stroke, post-stroke depression, 
dementias); (4) severe, life threatening conditions; (5) specific contraindications to tDCS, such as 
metallic plates in the head; (6) did not complete at least 2 visits to our research center; and (7) less 
than 8 years of schooling and/or difficulties in performing arithmetic operations, due to the nature 
of the CCT intervention performed, as described below. 
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 Regarding pharmacotherapy, we did not include patients taking antipsychotics and tricyclic 
antidepressants, as to avoid confounding factors and also because these treatments can interfere in 
other measurements we performed, such as heart rate variability and pupil dilation. All participants 
were in a stable drug dose regimen for at least 6 weeks - i.e. either based on Selective Serotonin 
Reuptake Inhibitors (SSRI) or Selective Noradrenalin Reuptake Inhibitors (SNRI). Benzodiazepine 
drugs were tolerated but tapered to a maximum of 20mg/d diazepam (or equivalent) according to 
previous findings suggesting that benzodiazepines could interfere in tDCS antidepressant 
mechanisms (Brunoni et al., 2013a; Brunoni et al., 2013c). 
 
2.1 Design  
Participants were randomized to (1) CCT with sham tDCS and (2) CCT with active tDCS 
(i.e., all participants received CCT). The trial duration was 4 weeks, entailing a short treatment 
period of 10 daily, consecutive tDCS and CCT sessions (first two weeks, except weekends) and the 
endpoint assessment two weeks after the end of the treatment period (i.e., week 4). The primary 
endpoint at week 4 was chosen a priori according to prior tDCS studies showing that greater tDCS 
effects are usually observed in this time frame. Also, amelioration of depressive symptoms usually 
occurs in this time frame.  Participants were allowed 2 nonconsecutive missed visits; in such cases 
extra tDCS sessions were performed to complete the total number of sessions. 
 The sample size was estimated based on previous findings from our group at the time of 
study design (Boggio et al., 2008), in which a 6-point difference in the HDRS scores between active 
vs. sham tDCS (SD=6) was observed. Therefore, with two-sided α=0.05 and β=0.2, we calculated 
that it would be necessary to enroll 32 patients to detect this 6-point difference between groups. 
Considering an attrition rate of 10-20%, we aimed to recruit 36 to 40 patients for this study. 
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2.2 Procedures 
 TDCS was administered using commercial devices (Chattanooga Ionto Device; Chattanoga 
group), which deliver a constant, fixed current by varying the voltage output according to resistance 
changes and turning off the current when the resistance is too high. For each active tDCS session, 
we applied a direct current of 2mA through 25cm2 saline-soaked rubber sponges for 30min/d. The 
anode and the cathode were respectively placed over F3 and F4 that correspond to the left and the 
right DLPFC. This montage, as described by Ferrucci et al. (2009), is advantageous to the 
placement of the cathode over the right supraorbital area as it simultaneously increases the left and 
decreases the right DLPFC activity, which are respectively hypo- and hyperactive in depression. 
The sham procedure consisted of an initial 30-second ramp-in phase, 30 seconds of active 
stimulation and a ramp-out phase of 15 seconds, a reliable sham method (Gandiga et al., 2006), 
with similar efficacy to placebo-pill blinding (Brunoni et al., 2013b). The electrode position and all 
other procedures were performed identically to the active tDCS. Trained nurses were responsible to 
deliver the tDCS sessions and were instructed to adopt the same procedures for both sham and 
active stimulation. They were also trained to turn off the device outside patient’s eyesight. 
 The CCT was a modified version of thePaced Auditory Serial Addition Task(PASAT, for a 
detailed description see (Siegle et al., 2007; Siegle et al., In press)). The original PASAT (Gronwall, 
1977) consists in successively presenting numeric digits, the participants were being asked to 
continuously sum the new digit to the digit that was just presented. This task activates the left 
prefrontal cortex (Audoin et al., 2005) and reflects multiple cognitive abilities, such as sustained 
attention, working memory, inhibitory control and processing speed (Gonzalez et al., 2006). As 
suggested by Siegle et al. (2007), who considered that the original PASAT could be frustrating for 
depressed subjects, we used an “adaptive”, slower version, which starts with a 3000ms inter-
stimulus interval and speeds up by 100ms when participants get four consecutive items correct. 
Conversely, it slows down by 100ms when participants miss four consecutive items, therefore 
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keeping the performance relatively constant and equating the task for difficulty across participants 
and sessions. CCT was delivered in the last 15 minutes of each active/sham tDCS session.  
For the CCT, the numbers (1 to 9) were recorded in Portuguese and presented in a random 
order to the participants, who had to perform the sum of the last two digits by selecting the correct 
response on the screen. Participantscompletedthree5-
minblockspersession,andtheywereinstructedtoconcentrateonthetaskandgetasmanyitemscorrectandtor
esumethetaskasquicklyaspossiblewhentheymadeanerror. 
 
2.3 Assessments 
 The primary efficacy outcome was the HDRS score throughout the trial. Secondary outcome 
was the Beck Depression Inventory (BDI) scores. Treatment-resistant depression was defined as 
failure to achieve clinical response after at least two antidepressant drug trials of adequate dose and 
duration (Berlim and Turecki, 2007). 
 This study also assessed several other outcomes such as salivary cortisol response, heart rate 
variability, electroencephalography, pupil dilation and rumination that could be reported in 
upcoming publications.  
 
2.4 Statistical analysis 
 All analyses were performed using Stata 12 (Statacorp LP), with 2-sided significance tests at 
the 5% significance level. Analyses were conducted in the sample of completers and in the 
intention-to-treat sample, in which missing data were considered to be at random and imputed 
according to the last observation carried forward. Missing data were considered to be missing at 
random.   
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 As previously defined per protocol (and registered in clinicaltrials.gov) our main analysis 
was performed in the intention-to-treat (ITT) sample, using the method of the last-observation 
carried forward (LOCF), in which missing observations are imputed with the last observed known 
values. Since the dropout rate was high, we also explored our results by using a dataset in which 
missing data were imputed using the multiple imputation predictive mean matching (PMM) 
technique using 10 imputations (M=10). We tested this approach because it might be better than the 
LOCF method to recover lost information due to missing data (Barnes et al., 2006). We also 
performed complete-case (CC) analysis (or listwise deletion, in which all cases without complete 
observations are not included in the analysis) for the main outcomes. 
 Clinical and demographic characteristics between groups were compared using t-tests and 
chi-square tests for continuous and categorical variables, respectively. For the primary outcome, we 
employed a mixed 2x3 analysis of variance (ANOVA), using HDRS scores as the dependent 
variable, Group (two levels: active tDCS with CCT; sham tDCS with CCT) as the between-subjects 
independent variable and Time (3 levels: baseline; 2 weeks; 4 weeks) as the within-subjects, 
repeated measures independent variable. The Mauchly’s sphericity test was applied to check for 
violations of sphericity. We performed follow-up independent t-tests to test differences between 
groups at each time point and paired t-tests to test the within group changes over time. 
The BDI scale and other time points were also analyzed as secondary outcomes. We also 
described response and remission rates at endpoint. Response was defined as a ≥50% of depression 
improvement from baseline and remission as an endpoint HDRS score ≤7.   
In the exploratory analysis, we first performed several simple general linear regression 
analyses to identify whether the predictors age, gender, length of depressive episode, age of 
depression onset, number of depressive episodes, treatment-resistant depression, benzodiazepine 
use, improvement in the task performance throughout the stimulation period (hereby referred as 
“PASAT improvement”) and baseline inter-stimulus interval (ISI) on the PASAT were associated 
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with depression improvement.In this model, the dependent variable was the HDRS score change 
between baseline and week 4. The independent variables were group (dummy-coded in 0 and 1), the 
predictor and the interaction between group and the predictor. 
Of note, inpriorstudies(Siegle et al.; Siegle et al., In press), the median inter-stimulus 
interval (ISI) onthePASAT was computedforeachparticipant,and the mean of the median was 
examinedacrossparticipants. Here, our aim was to take into account the sequential adaptation in 
performance over each day of the training as to assess the progressive gains in cognitive 
performance throughout the trial.Therefore,inthecurrentstudy, the regression slope was used to 
assess PASAT improvement. In order to compute this variable, we first extracted the median ISI of 
each session (total of 10 sessions). After that, we performed a linear regression using the median ISI 
and day of training as dependent and independent variables, respectively. The slope of the model 
was used as an index of PASAT improvement throughout the trial. For visualization purposes, 
themorepositivetheslope,thefastertheparticipantsexecutedthePASATwithouterrors,andthusthebettert
heimprovementoverthecourseofthetraining. 
In a final step, we also performedmultiple regression analysis using different p cut-offs for 
variable inclusion (≤0.05, ≤0.1 and ≤0.15). In this method, only significant (according to the p cut-
off) predictors in the simple regression analysis are included in the multiple regression analyses. We 
used similar methodology in a previous study (Brunoni et al., 2013a).  
 
3. Results 
 Approximately 200 potential volunteers were screened to participate in the study. Of them, 
160 were excluded, as they did not attend to the eligibility criteria. The included patients were 
randomized to the active tDCS + CCT and sham tDCS + CCT groups. The groups were similar in 
clinical and demographic characteristics at baseline (Table 1). Importantly, 3 of the 40 participants 
were not included in our analyses due to trial abandonment (i.e., did not complete at least 2 visits to 
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our research center, n=2) and technical reasons (n=1, one participant with bipolar depression who 
was mistakenly diagnosed as unipolar depression during trial enrollment).  
Four patients dropped-out at week 2 and 13 patients dropped-out at week 4. The dropouts 
were evenly distributed between groups (Figure 1). All patients tolerated tDCS well, without 
adverse effects.  
(Table 1) 
(Figure 1) 
  
3.1 Main outcomes 
 No violations of sphericity were observed in all analyses. In the ITT analysis, we observed 
significant main effects of time (F2,110=12.21, p<0.01) but no significant main effects of group 
(F1,110=0.19, p=0.66) and of the interaction of time x group (F2,110=0.05, p=0.94). Follow-up 
independent t-tests showed that the groups presented no significant differences at any time point 
(Table 1). Moreover, paired t-tests revealed that depression significantly improved from baseline to 
week 2 and week 4 (t=2.7, p=0.01 and t=2.77, p<0.01, respectively) in the sham tDCS + CCT and 
also in the active tDCS + CCT (t=2.35, p=0.02 and t=2.85, p<0.01, respectively). In other words, 
there were no baseline depression differences between groups, and both groups showed similar 
depression improvement. 
 Similar results were observed with the BDI scale and for the ITT and CC analyses (Table 2). 
Finally, the analysis using the multiple imputation PMM approach also yielded similar results (data 
not shown).   
(Table 2) 
3.2 Simple linear regression analysis 
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 In the simple linear regression analysis only age (F1,34=5.82, p=0.02) was significantly 
associated with the outcome, with a superior improvement in younger patients. (Table 3) 
 
(Table 3) 
3.3 Multiple linear regression analysis 
Only age was significantly associated with the outcome for all p cut-offs and only “PASAT 
improvement” was associated with the outcome at the p cut-off of ≤0.15. Therefore, we performed 
only one analysis, which explored the influence of age and PASAT improvement with the outcome. 
In the exploratory model, we found no main effects of PASAT improvement (F1,29=2.29, p=0.14), 
age (F1,29=0.19, p=0.66) and the interaction of age with PASAT improvement (F1,29=1.65, p=0.2). 
Nonetheless, we found trends for the main effects of tDCS (F1,29=3.73, p=0.06), with a trend of 
superior improvement in the active tDCS + CCT vs. sham tDCS + CCT groups; and of the 
interaction of tDCS with age (F1,29=3.84, p=0.06), with a trend of superior improvement in the 
active vs. sham groups with increasing age. We found significant effects of the interaction of tDCS 
with PASAT improvement (F1,29=6.51, p=0.02), with superior improvement in the active vs. sham 
groups directly associated with task performance. Finally, the triple interaction of tDCS, age and 
PASAT improvement (F1,29=7.18, p=0.01) was significant, with a greater difference in the active 
tDCS + CCT vs. sham tDCS + CCT groups directly associated with age and task improvement, as 
depicted in Figure 2. In other words, PASAT improvement and age influenced the effects of active 
tDCS + CCT in depression, with older age and greater PASAT improvement being associated with 
increased difference in depression improvement in active vs. sham groups. 
 
(Figure 2) 
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4. Discussion 
 In this randomized, double-blinded trial assessing the efficacy of cognitive control therapy 
alone (n=17) and combined with tDCS (n=20) in major depression; CCT alone and combined with 
tDCS ameliorated depressive symptoms immediately after the acute treatment period (week 2) and 
at endpoint (week 4). Exploratory analyses revealed a superior improvement in depressive 
symptoms for the combined therapy when taking into account age and improvement in the PASAT 
performance throughout the trial. Specifically, older age was associated with greater enhancement 
of tDCS on CCT, and patients who presented greater PASAT improvement during the task were 
those who improved more in their depressive symptoms. These findings are discussed below.  
 To the best of our knowledge, only Segrave et al. (2013) had previously explored the 
efficacy of CCT combined with tDCS. In a 3-arm, double-blinded, sham-controlled trial, they 
randomized 27 patients to receive CCT with sham tDCS, tDCS with sham CCT and both therapies 
combined. Similarly to our study, all groups presented improvement in depressive symptoms after 5 
days of tDCS and/or CCT therapy. However, they found that only the tDCS + CCT group presented 
a sustained depression improvement at follow-up; whereas we found that both groups, including the 
sham tDCS + CCT group, also sustained improvement during follow-up. However, their study and 
ours have several methodological differences that might explain these contrasting outcomes, such 
as: (1) we performed more tDCS/CCT sessions (5 vs. 10 days) and we used only one (vs. two) 
training task and (2) our follow-up period was relatively shorter (2 vs. 3 weeks) and had more 
dropouts than theirs.  
 In addition, we might have not identified a superior synergistic effect of tDCS with CCT – 
as found in Segrave et al. – for some methodological reasons, which include:  
(1) a ceiling effect of the CCT intervention, which could have impaired the signal detection 
between active vs. sham groups;  
 14
(2) the high number of dropouts between weeks 2 and 4 that could have also converged the mean 
depression scores of the groups – although we cannot explain the high dropout rate at week 4, we 
anecdotally observed that patients complained to perform the EEG sessions, which were very time 
consuming. As the second EEG was scheduled at week 4, they could have not returned to the 
session for this reason; and 
(3) the high variance in the final HDRS scores (as observed in SD scores around 10, much higher 
than initially predicted in our power analyses), which suggested an unexplained source of 
heterogeneity influencing the outcomes.  
 Therefore, in order to identify variables associated with heterogeneity, we performed simple 
and multiple linear regression exploratory models. We found that PASAT improvement and age 
wererelated tothe outcome. From a biological perspective, this model is interesting because PASAT 
performance decreases with age (Tombaugh, 2006) and tDCS effects in cognitive processing are 
also influenced by age (Berryhill and Jones, 2012; Meinzer et al., 2013). Furthermore, cognitive 
processing - the basis of the clinical effects of CCT (Siegle et al., 2007; Siegle et al., In press) - 
decreases with age and can be enhanced by tDCS in older individuals (Berryhill and Jones, 2012; 
Holland et al., 2011; Meinzer et al., 2013); and prefrontal atrophy is observed with ageing 
(Lemaitre et al., 2012).  
The findings of our exploratory analyses (Figure 2) showed that for older patients the 
clinical effects of active tDCS + CCT were observedaccording to task improvement throughout the 
trial. This suggests that this combined intervention might be particularly effective in older 
individuals who still have cognitive resources to adequately learn and improve task performance 
over time. In fact, the ceiling effect of CCT could be more important in younger compared to older 
patients who have (even in the absence of degenerative diseases) volume reduction in several brain 
areas, particularly the prefrontal cortex (Lemaitre et al., 2012).  
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The specific mechanisms of action of tDCS in older adults are still being investigated in 
literature, however our hypothesis is that some of these individuals, with decreased cognitive 
resources due to cortical atrophy and cognitive decline, can particularly benefit from focal (CCT) 
and non-focal (tDCS) interventions aiming to increase prefrontal cortical activity compared to 
younger adults. Although our exploratory findings should be confirmed in future studies 
specifically targeting older adults; they are clinically relevant considering the worldwide ageing of 
population and the limited efficacy of pharmacotherapy in this group, in which adverse effects are 
an important issue(Sanglier et al., 2011). In this regard, the development of effective therapies 
without clinical adverse effects is particularly relevant. 
 
4.1 Limitations 
Some limitations of our study should be underscored. First, the higher number of dropouts 
could have lead to false-negative findings. Although we performed our data analysis with different 
approaches (ITT, CC and multiple imputation PMM), the results were similar. Another limitation is 
that we did not have a pure placebo arm, therefore we were not able to examine directly whether the 
treatment groups would have presented a superior response than a placebo group – although we 
observed a response rate of 25%, which is a similar magnitude than found in single- and double-
blind tDCS studies(Berlim et al., 2013; Brunoni et al., 2012). 
 
5. Conclusion 
 In this randomized, double-blind, sham-controlled trial we investigated whether tDCS could 
enhance the efficacy of CCT in the treatment of depression. Our main outcome showed that both 
groups similarly improved over time. However, exploratory analyses revealed that tDCS augmented 
the clinical effects of CCT in older individuals, particularly in those who presented improvement in 
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the cognitive task performed throughout the trial. We hypothesize that this combined therapy might 
be particularly relevant in this subgroup that is more prone to present cognitive decline and 
prefrontal cortical atrophy. Nonetheless, confirmatory trials exploring the effects of CCT with tDCS 
in geriatric depression are warranted. 
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Table 1. Clinical and demographic characteristics at baseline.  
  Sham tDCS + CCT Active tDCS + CCT p 
Male / Female 13/4 13/7 0.45 
Age, years (SD) 41.5 (10.6) 46.1 (10.4) 0.2 
N (SD) previous depressive episodes 6.3 (6.2) 4.4 (4.3) 0.44 
Duration of current episode, months (SD) 9.2 (9.2) 17.4 (15.8) 0.09 
Age of depression onset, year (SD) 23.5 (12.2) 29.6 (11.7) 0.15 
Treatment resistant depression, n (%) 7 (41) 7 (35) 0.7 
Benzodiazepine-use, n (%) 6 (35) 4 (20) 0.3 
HAMD-21, mean (SD) 27 (5.7) 25.6 (5.8) 0.5 
BDI, mean (SD) 34 (8.2) 30.8 (7.4) 0.25 
ISI, ms (SD) 4088 (744) 3957 (913) 0.64 
HDRS-21, Hamilton Depression Rating Score, 21-items; BDI, Beck Depression Inventory, ISI, 
interstimulus interval (from the PASAT test). Values represent mean (standard deviation) for 
continuous variables and number (%) of cases for categorical variables. 
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Table 2. Depression scores during the trial. 
  Intention-to-treat Completers 
  n 
Sham tDCS 
+ CCT 
Active 
tDCS + 
CCT 
p n Sham tDCS 
+ CCT 
Active tDCS 
+ CCT p 
HDRS-21 
 
  
  
  
 Baseline 17 / 20 27 (5.7) 26 (5.8) 0.5 17 / 20 27 (5.7) 26 (5.8) 0.5 
Week 2 17 / 20 20 (9) 20 (9.8) 0.91 14 / 19 19 (10) 20 (10) 0.89 
Week 4 17 / 20 20 (8.7) 19 (9.3) 0.71  7 / 13 20 (10) 16 (8) 0.28 
Responders (week 4) -- 4 (23) 5 (25) 0.9 -- 1 (14) 5 (38) 0.26 
Remitters (week 4) -- 2 (11) 1 (5) 0.4 -- 1 (14) 1 (7) 0.64 
BDI 
        
Baseline 15 / 18 34 (8) 31 (7.5) 0.25 15 / 18 34 (8) 31 (7.5) 0.25 
Week 2 15 / 18 23 (12) 23 (12) 0.97 13 / 17 22 (13) 21 (11) 0.82 
Week 4 15 / 18 24 (11.4) 21 (10.3) 0.54 10/12 24 (12) 20 (10) 0.35 
 
HDRS-21, Hamilton Depression Rating Score, 21-items; BDI, Beck Depression Inventory. Values 
represent mean (standard deviation) scores except for responders and remitters, in which the values 
represent number (%) of cases.  
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Table 3. Analysis of predictors of response. 
Variable F Degrees of freedom p 
Age 5.82 1,34 0.02 
Gender 0.52 1,34 0.47 
Number of depressive episodes 1.23 1,34 0.28 
Duration of current episode 0.01 1,34 0.98 
Age of depression onset 1.24 1,34 0.27 
Treatment-resistant depression 0.07 1,34 0.78 
Benzodiazepine use 1.78 1,34 0.2 
PASAT improvement 2.15 1,34 0.15 
Baseline ISI 0.08 1,34 0.78 
ISI, inter-stimulus interval. PASAT, Paced Auditory Serial Addition Task. 
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Figure 1. Flow chart of the study.  
 
Figure 2. Depression improvement (y axis, higher scores indicating improvement) vs. Cognitive 
task (“PASAT”) improvement (x axis, higher scores indicate better performance) in patients 
younger and older than 50 years-old. In younger patients, active vs. sham tDCS present similar 
scores regardless of PASAT improvement. In older patients, active vs. sham tDCS are different 
according to PASAT improvement, with greater depression improvement in those who presented 
better performance in the task, for the active tDCS group. Error bars indicate standard deviation. 
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